Answers are grounded in this paper and cite their sources.
Introduction X-linked Alport syndrome (XLAS) is a hereditary nephropathy caused primarily by mutations in the COL4A5 gene and is characterized by progressive nephritis, hearing loss, and ocular abnormalities. Early diagnosis and the identification of specific biomarkers are critical for the effective management of XLAS. Methods We developed a laser desorption/ionization mass spectrometry (LDI-MS) metabolomics approach based on a gold nanowire-modified MXene (MXene@AuNWs) nanoplatform to acquire the metabolic fingerprints of urine and serum from XLAS patients and healthy controls. The platform combines the high ionization efficiency of AuNWs with the ordered two-dimensional structure and abundant surface terminations of MXene, enabling the selective enrichment and sensitive detection of small-molecule metabolites; urinary homocysteine and serum phenylalanine hydroxylase (PAH) were quantified by an orthogonal enzyme-linked immunosorbent assay (ELISA). Results The platform tolerated high concentrations of salt and protein and was applicable to both urine and serum. The metabolite at m/z 278.43, assigned to urinary homocysteine, was the finding most significantly associated with XLAS (AUC = 0.752), and the ELISA independently confirmed a significantly decreased urinary homocysteine level in patients, whereas serum PAH showed no significant difference between the groups. Discussion These results establish MXene@AuNWs-assisted LDI-MS metabolic fingerprinting, cross-validated by immunoassay, as a rapid and label-free route to biomarker discovery in XLAS, and hold substantial potential for future clinical applications.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: